Page "Gerovital" Paragraph 8

Some clinical trials in the mid-to-late 1970s suggested that Gerovital H3 acts as a weak, competitive, reversible MAO inhibitor, and so may have some antidepressant value, but otherwise has negligible effect on disease ( see Clinical Trials, below ).

In 1994, the U. S. FDA Consumer magazine said: " No health claims for Gerovital have been substantiated, and FDA considers it an unapproved new drug.

It has caused low blood pressure, respiratory difficulties, and convulsions in some users.

" Suppliers assert that the product is safe, and one cites a brief quotation from a newspaper article that says " while as early as 1973 Elmer Gardner of the FDA's Bureau of Drugs stated ' There is no safety problem with Gerovital H-3.

'"